ZFP42

Summary

ZFP42 (ZFP42 zinc finger protein, HGNC:30949) is a protein-coding gene on chromosome 4q35.2, encoding Zinc finger protein 42 homolog (Q96MM3). Involved in the reprogramming of X-chromosome inactivation during the acquisition of pluripotency.

Enables sequence-specific double-stranded DNA binding activity. Involved in female gonad development and male gonad development. Located in cytoplasm.

Source: NCBI Gene 132625 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 64 total — 1 pathogenic
• Transcription factor: yes — 21 downstream targets (CollecTRI)
• MANE Select transcript: NM_174900

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30949
Approved symbol	ZFP42
Name	ZFP42 zinc finger protein
Location	4q35.2
Locus type	gene with protein product
Status	Approved
Aliases	REX1, ZNF754
Ensembl gene	ENSG00000179059
Ensembl biotype	protein_coding
OMIM	614572
Entrez	132625

Gene structure

Transcript identifiers

Ensembl transcripts: 26 — 26 protein_coding

ENST00000326866, ENST00000509524, ENST00000618147, ENST00000940024, ENST00000940025, ENST00000940026, ENST00000940027, ENST00000940028, ENST00000940029, ENST00000940030, ENST00000940031, ENST00000940032, ENST00000940033, ENST00000940034, ENST00000940035, ENST00000940036, ENST00000940037, ENST00000940038, ENST00000940039, ENST00000940040, ENST00000940041, ENST00000940042, ENST00000940043, ENST00000940044, ENST00000940045, ENST00000940046

RefSeq mRNA: 2 — MANE Select: NM_174900 NM_001304358, NM_174900

CCDS: CCDS3849

Canonical transcript exons

ENST00000326866 — 4 exons

Exon	Start	End
ENSE00001515523	187999609	187999685
ENSE00001515525	187999108	187999273
ENSE00001515526	187995771	187995840
ENSE00002020347	188002713	188005046

Expression profiles

Bgee: expression breadth broad, 33 present calls, max score 88.18.

FANTOM5 (CAGE): breadth broad, TPM avg 3.9185 / max 289.9133, expressed in 202 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
50927	3.8523	200
50929	0.0662	32

Top tissues by expression

239 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	88.18	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	84.73	gold quality
amniotic fluid	UBERON:0000173	76.58	gold quality
sperm	CL:0000019	74.71	silver quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	73.81	gold quality
tendon of biceps brachii	UBERON:0008188	66.04	silver quality
placenta	UBERON:0001987	57.64	gold quality
testis	UBERON:0000473	56.25	gold quality
medial globus pallidus	UBERON:0002477	55.83	gold quality
right testis	UBERON:0004534	55.64	gold quality
left testis	UBERON:0004533	54.41	gold quality
cardiac muscle of right atrium	UBERON:0003379	54.34	gold quality
cartilage tissue	UBERON:0002418	54.23	silver quality
left ventricle myocardium	UBERON:0006566	54.23	gold quality
pancreatic ductal cell	CL:0002079	54.17	silver quality
epithelial cell of pancreas	CL:0000083	53.94	gold quality
kidney epithelium	UBERON:0004819	53.93	gold quality
upper arm skin	UBERON:0004263	53.52	gold quality
ileal mucosa	UBERON:0000331	53.16	silver quality
globus pallidus	UBERON:0001875	52.45	gold quality
tibialis anterior	UBERON:0001385	52.32	silver quality
upper leg skin	UBERON:0004262	51.25	gold quality
ventricular zone	UBERON:0003053	51.11	silver quality
myocardium	UBERON:0002349	50.25	gold quality
deltoid	UBERON:0001476	48.62	gold quality
skin of hip	UBERON:0001554	47.17	silver quality
nasal cavity epithelium	UBERON:0005384	47.03	gold quality
tendon	UBERON:0000043	46.99	gold quality
ganglionic eminence	UBERON:0004023	46.58	silver quality
quadriceps femoris	UBERON:0001377	46.52	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-MTAB-6819	yes	411.11
E-MTAB-9388	yes	6.51
E-ANND-3	yes	4.11
E-MTAB-9801	no	2.56

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

21 targets.

Target	Regulation
AKT1
BDKRB2
BMP4
CCNB1	Activation
CCNB2
DKK1
DPPA4
DPPA5
FGF4
LEFTY2
LIN28A
MAP2K3	Unknown
MIR302A	Unknown
PIK3R1
RLIM
SLU7
SOCS3
SPARC
THY1
UTF1
ZFP42	Activation

JASPAR motifs

Motif	Name	Family
MA1651.1	ZFP42	More than 3 adjacent zinc fingers
MA1651.2	ZFP42	More than 3 adjacent zinc fingers

JASPAR matrix evidence (PMIDs): PMID:28473536

Upstream regulators (CollecTRI, top): NANOG, NR0B1, POU2F1, POU3F1, POU5F1, SOX2, YY1, ZFP42, ZNF263

miRNA regulators (miRDB)

40 targeting ZFP42, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-767-5P	99.95	70.85	993
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-10523-5P	99.91	69.22	2038
HSA-MIR-3140-3P	99.88	68.47	2069
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-6079	99.84	68.54	1170
HSA-MIR-4799-5P	99.82	70.60	2663
HSA-MIR-4694-3P	99.79	69.53	2640
HSA-MIR-587	99.64	70.86	2611
HSA-MIR-4437	99.52	65.29	1266
HSA-MIR-3182	99.40	68.15	2454
HSA-MIR-148A-5P	99.30	68.27	1141
HSA-MIR-1264	99.25	66.81	1317
HSA-MIR-4477B	99.23	70.49	1733
HSA-MIR-122B-3P	99.21	68.90	1333
HSA-MIR-21-3P	99.21	68.95	1312
HSA-MIR-661	99.09	65.94	2062
HSA-MIR-3168	99.08	67.75	1384

Literature-anchored findings (GeneRIF, showing 11)

• MAPCs express the OCT4 and REX1 transcription factors, two specific markers of undifferentiated embryonic stem (ES) cells. (PMID:15790780)
• REX1 functions in normal adult epithelial cells and tumorigenic stem cells. (PMID:16865673)
• Data show that Oct-4, Rex-1, and Gata-4 expression in human mesenchymal stem cells increases cell differentiation efficiency but not hTERT expression. (PMID:17211834)
• expression of REX-1 in meiotic cells from both testes and ovary indicate a role in meiosis. (PMID:18281244)
• hRex1 binds to the hRex1 promoter region at -298 bp and positively regulates hRex1 transcription, but this regulation is lost in PC-3 human prostate cancer cells. (PMID:20232320)
• reduced expression protein-1 (REX-1) is widely expressed in human skin and may be involved in cutaneous differentiation but not in stem cell fate determination. (PMID:21446939)
• Results show that a novel pluripotency regulator, REX1, is essential for pluripotency and reprogramming. (PMID:23939908)
• Results provide evidence that bFGF regulates stemness maintenance in stem cells isolated from human exfoliated deciduous teeth (SHEDs) by enhancing REX-1 mRNA expression via the FGFR and Akt signaling pathways. Moreover, IL-6 is also involved in the bFGF-induced REX1 expression. (PMID:27883224)
• ZFP42 missense mutation was identified in patients with multilocus imprinting disturbances. ZFP42 pathogenic mutation affects protein conformation and activity. (PMID:30221575)
• REX1 overexpression could play a crucial role in the metastasis and invasion of cervical cancer by upregulating the activity of the JAK2/STAT3 pathway by trans-suppressing SOCS1 expression. (PMID:31409905)
• REX-1 Represses RASSF1a and Activates the MEK/ERK Pathway to Promote Tumorigenesis in Prostate Cancer. (PMID:34183450)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
mus_musculus	Zfp42	ENSMUSG00000051176
rattus_norvegicus	Zfp42	ENSRNOG00000063726
rattus_norvegicus	Zfp42	ENSRNOG00000067356
drosophila_melanogaster	phol	FBGN0035997
caenorhabditis_elegans		WBGENE00011639

Paralogs (2): YY1 (ENSG00000100811), YY2 (ENSG00000230797)

Protein

Protein identifiers

Zinc finger protein 42 homolog — Q96MM3 (reviewed: Q96MM3)

Alternative names: Reduced expression protein 1, Zinc finger protein 754

All UniProt accessions (1): Q96MM3

UniProt curated annotations — full annotation on UniProt →

Function. Involved in the reprogramming of X-chromosome inactivation during the acquisition of pluripotency. Required for efficient elongation of TSIX, a non-coding RNA antisense to XIST. Binds DXPas34 enhancer within the TSIX promoter. Involved in ES cell self-renewal.

Subcellular location. Nucleus.

Tissue specificity. Expressed in kidney, epidermal keratinocytes, prostate epithelial cells, bronchial and small airway lung epithelial cells (at protein level). Expressed in malignant kidney and several carcinoma cell lines (at protein level). Expressed in embryonic stem cells, kidney, epidermal keratinocytes, prostate epithelial cells, bronchial and small airway lung epithelial cells. Expressed in embryonal carcinomas, seminomas, malignant kidney and several carcinoma cell lines.

Post-translational modifications. Polyubiquitinated by RNF12, leading to proteasomal degradation.

Induction. Down-regulated upon retinoic acid addition to F9 stem cells.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

RefSeq proteins (2): NP_001291287, NP_777560* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily

Pfam: PF00096

UniProt features (10 total): zinc finger region 4, cross-link 2, chain 1, region of interest 1, compositionally biased region 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96MM3-F1	57.15	0.27

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 231, 233

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 75 (showing top): LI_CISPLATIN_RESISTANCE_DN, MUELLER_PLURINET, GOBP_REPRODUCTIVE_SYSTEM_DEVELOPMENT, chr4q35, GOBP_FEMALE_SEX_DIFFERENTIATION, GOBP_SEX_DIFFERENTIATION, BERTUCCI_MEDULLARY_VS_DUCTAL_BREAST_CANCER_UP, GOBP_DEVELOPMENTAL_PROCESS_INVOLVED_IN_REPRODUCTION, CONRAD_STEM_CELL, YAMAZAKI_TCEB3_TARGETS_DN, GOBP_MALE_SEX_DIFFERENTIATION, GOBP_DEVELOPMENT_OF_PRIMARY_SEXUAL_CHARACTERISTICS, GOBP_MEIOTIC_CELL_CYCLE, GOCC_PCG_PROTEIN_COMPLEX, GOCC_TRANSCRIPTION_REGULATOR_COMPLEX

GO Biological Process (4): regulation of transcription by RNA polymerase II (GO:0006357), male gonad development (GO:0008584), female gonad development (GO:0008585), meiotic cell cycle (GO:0051321)

GO Molecular Function (8): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription factor activity (GO:0003700), zinc ion binding (GO:0008270), sequence-specific double-stranded DNA binding (GO:1990837), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (5): chromatin (GO:0000785), transcription regulator complex (GO:0005667), cytoplasm (GO:0005737), PcG protein complex (GO:0031519), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	2
gonad development	2
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
cellular anatomical structure	2
transcription by RNA polymerase II	1
development of primary male sexual characteristics	1
development of primary female sexual characteristics	1
cell cycle	1
sexual reproduction	1
reproductive process	1
meiotic nuclear division	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
transcription cis-regulatory region binding	1
transcription regulator activity	1
transition metal ion binding	1
double-stranded DNA binding	1
sequence-specific DNA binding	1
nucleic acid binding	1
binding	1
cation binding	1
chromosome	1
protein-containing complex	1
intracellular anatomical structure	1
nuclear protein-containing complex	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1178 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZFP42	NANOG	Q9H9S0	820
ZFP42	ESRRB	O95718	724
ZFP42	POU5F1	P31359	715
ZFP42	DPPA3	Q6W0C5	696
ZFP42	SOX2	P48431	694
ZFP42	UTF1	Q5T230	665
ZFP42	DPPA4	Q7L190	626
ZFP42	RYBP	Q8N488	625
ZFP42	TFCP2L1	Q9NZI6	624
ZFP42	GDF3	Q9NR23	602
ZFP42	TBX3	O15119	597
ZFP42	DPPA2	Q7Z7J5	597
ZFP42	CRIPTO	P13385	596
ZFP42	DPPA5	A6NC42	593
ZFP42	FBXO15	Q8NCQ5	585

IntAct

17 interactions, top by confidence:

A	B	Type	Score
MEOX2	ZFP42	psi-mi:“MI:0915”(physical association)	0.560
PIAS2	ZFP42	psi-mi:“MI:0915”(physical association)	0.560
LHX2	ZFP42	psi-mi:“MI:0915”(physical association)	0.560
SUMO1	ZFP42	psi-mi:“MI:0915”(physical association)	0.560
RNF4	ZFP42	psi-mi:“MI:0915”(physical association)	0.560
ZFP42	EEF1A2	psi-mi:“MI:0914”(association)	0.350
ZFP42	MEOX2	psi-mi:“MI:0915”(physical association)	0.000
ZFP42	PIAS2	psi-mi:“MI:0915”(physical association)	0.000
ZFP42	LHX2	psi-mi:“MI:0915”(physical association)	0.000
ZFP42	SUMO1	psi-mi:“MI:0915”(physical association)	0.000
ZFP42	RNF4	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (17): ZFP42 (Affinity Capture-MS), ZFP42 (Two-hybrid), ZFP42 (Two-hybrid), ZFP42 (Two-hybrid), ZFP42 (Two-hybrid), ZFP42 (Two-hybrid), ZFP42 (Affinity Capture-MS), ZFP42 (Affinity Capture-MS), AGO4 (Affinity Capture-MS), EEF1A2 (Affinity Capture-MS), ZFP42 (Affinity Capture-MS), PPIA (Cross-Linking-MS (XL-MS)), YAF2 (Two-hybrid), EED (Two-hybrid), RYBP (Two-hybrid)

ESM2 similar proteins: A0JPK3, A1YFX5, A2RQG7, A7KBS4, F4JUI3, G3X9G7, O49498, P03131, P04605, P04614, P05909, P0C1K0, P11332, P12453, P18098, P24109, P35965, P98182, Q09424, Q0VCB0, Q19203, Q2YDJ5, Q3UZB0, Q567C6, Q5BI31, Q5EXX3, Q5M948, Q62396, Q6AXY9, Q6PB60, Q6PI77, Q71HP2, Q74124, Q7JUR5, Q7Z142, Q7Z2Y5, Q80YD3, Q86UQ0, Q8C0P7, Q8C6P8

Diamond homologs: A0JC51, A2ANX9, O15391, O57311, O57415, O60481, O62836, O73689, O95409, P08048, P0C6P6, P10925, P17010, P17012, P18747, P20662, P22227, P25490, P34694, P46684, P80944, Q00899, Q10RP4, Q12145, Q15915, Q29419, Q2FAY8, Q3TTC2, Q3UH06, Q3US17, Q3Y4E1, Q52V16, Q5NVT2, Q5R782, Q5RJ54, Q61467, Q61624, Q62520, Q62521, Q62806

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
POU5F1	“up-regulates quantity by expression”	ZFP42	“transcriptional regulation”
RLIM	“down-regulates quantity by destabilization”	ZFP42	ubiquitination

Disease & clinical

Clinical variants and AI predictions

ClinVar

64 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	46
Likely benign	7
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
979496	GRCh37/hg19 4q35.2(chr4:187391214-190957473)x1	Pathogenic

SpliceAI

526 predictions. Top by Δscore:

Variant	Effect	Δscore
4:187995838:GGG:G	donor_gain	1.0000
4:187995839:GGG:G	donor_gain	1.0000
4:187995839:GG:G	donor_gain	0.9900
4:187995840:GG:G	donor_gain	0.9900
4:187995841:G:GA	donor_loss	0.9900
4:187995841:G:GG	donor_gain	0.9900
4:187995842:T:G	donor_loss	0.9900
4:187999274:GT:G	donor_gain	0.9800
4:187995837:AGGG:A	donor_gain	0.9600
4:187995838:GGGG:G	donor_gain	0.9600
4:187995836:CAGGG:C	donor_gain	0.9500
4:187995840:G:T	donor_gain	0.9500
4:187997716:G:GG	donor_gain	0.9400
4:187999607:A:AG	acceptor_gain	0.9300
4:187999608:G:GG	acceptor_gain	0.9300
4:188001322:A:AG	donor_gain	0.9300
4:188001323:G:GG	donor_gain	0.9300
4:188002709:GCAGG:G	acceptor_loss	0.9300
4:188002710:CAG:C	acceptor_loss	0.9300
4:188002711:A:AC	acceptor_loss	0.9300
4:188002712:GGT:G	acceptor_gain	0.9300
4:187997715:A:AG	donor_gain	0.9200
4:188002702:T:G	acceptor_loss	0.9200
4:188001319:T:TG	donor_gain	0.8900
4:187999271:GAAGT:G	donor_gain	0.8800
4:188002701:A:AG	acceptor_loss	0.8800
4:187997505:GC:G	donor_gain	0.8700
4:187997653:A:G	acceptor_gain	0.8700
4:188002709:G:GA	acceptor_gain	0.8600
4:188002708:A:AG	acceptor_gain	0.8200

AlphaMissense

2032 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:188003573:T:C	F256L	1.000
4:188003575:C:A	F256L	1.000
4:188003575:C:G	F256L	1.000
4:188003636:T:C	C277R	1.000
4:188003462:T:C	C219R	0.999
4:188003483:T:C	F226L	0.999
4:188003485:C:A	F226L	0.999
4:188003485:C:G	F226L	0.999
4:188003546:T:A	C247S	0.999
4:188003546:T:C	C247R	0.999
4:188003547:G:C	C247S	0.999
4:188003548:C:G	C247W	0.999
4:188003574:T:C	F256S	0.999
4:188003636:T:A	C277S	0.999
4:188003637:G:C	C277S	0.999
4:188003638:T:G	C277W	0.999
4:188003663:T:C	F286L	0.999
4:188003664:T:C	F286S	0.999
4:188003665:T:A	F286L	0.999
4:188003665:T:G	F286L	0.999
4:188003375:T:C	C190R	0.998
4:188003377:T:G	C190W	0.998
4:188003464:T:G	C219W	0.998
4:188003471:T:C	C222R	0.998
4:188003484:T:C	F226S	0.998
4:188003600:C:G	H265D	0.998
4:188003602:C:A	H265Q	0.998
4:188003602:C:G	H265Q	0.998
4:188003607:G:C	R267P	0.998
4:188003612:C:G	H269D	0.998

dbSNP variants (sampled 300 via entrez): RS1000017269 (4:188004848 A>T), RS1000238244 (4:188000441 G>A), RS1000619195 (4:187995288 C>A,G,T), RS1000678515 (4:188000692 A>G), RS10008065 (4:188005444 C>A), RS1000860872 (4:188000244 G>A,C,T), RS1000962575 (4:187994789 A>C,G), RS1001280234 (4:187999445 T>G), RS1001393699 (4:188004797 A>G), RS1001626346 (4:187994004 T>C), RS1001648080 (4:187999158 G>C,T), RS1001687771 (4:188003692 C>T), RS1001705444 (4:187993780 T>C), RS1002238879 (4:187997902 G>A), RS1002270051 (4:187998131 G>C)

Disease associations

OMIM: gene MIM:614572 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST004635_11	Testicular germ cell tumor	2.000000e-12
GCST004713_3	Testicular germ cell tumor	3.000000e-08
GCST004780_10	Cortisol levels (saliva)	8.000000e-06
GCST008473_9	Visceral fat	2.000000e-06
GCST012319_12	LDL levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	6.000000e-06

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0005843	cortisol measurement
EFO:0004611	low density lipoprotein cholesterol measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

21 total (human), top 21 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	6
methylmercuric chloride	decreases expression, increases expression	3
trichostatin A	affects cotreatment, increases expression	3
sodium arsenite	increases expression	2
entinostat	increases expression, affects cotreatment	2
belinostat	increases expression, affects cotreatment	2
Vorinostat	affects cotreatment, increases expression	2
Panobinostat	affects cotreatment, increases expression	2
Benzo(a)pyrene	increases mutagenesis, affects methylation, increases methylation	2
arsenite	decreases expression, increases methylation	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment	1
abrine	increases expression	1
dorsomorphin	increases expression, affects cotreatment	1
(+)-JQ1 compound	decreases expression	1
Acetaminophen	increases expression	1
Indomethacin	increases expression	1
Malathion	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Tretinoin	decreases expression	1
Asbestos, Serpentine	decreases methylation	1
Antirheumatic Agents	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.